ERBB3 and melanoma: Many studies over the past 5 years have linked resistance to B-RAF/MEK inhibitors in B-RAF V600E mutated melanoma to correlate with evolutionary survival-induced activation of ERBB family receptors, including ERBB1 and ERBB3 (33–36).